DarioHealth Finalizes $20M At-The-Market Offering, Signaling Significant Dilution to Fund Operations

summarizeSummary

DarioHealth has finalized the terms for an At-The-Market offering to sell up to $20 million in common stock, a move critical for funding operations but highly dilutive to existing shareholders.

check_boxKey Events

• Finalizes $20M At-The-Market Offering

  DarioHealth Corp. has filed a prospectus supplement to sell up to $20 million of common stock through an At-The-Market (ATM) equity offering program with A.G.P./Alliance Global Partners. This finalizes the terms of the program announced in an 8-K earlier today.

• Significant Potential Dilution

  The offering could result in the issuance of approximately 2.47 million new shares, representing a potential dilution of about 33.78% based on current outstanding shares and the last reported sale price of $8.11 per share.

• Proceeds for Working Capital and Debt Repayment

  Net proceeds are intended for commercial, sales and marketing activities, research and development, mergers and acquisitions, corporate activities, repayment of a $50 million credit facility, and general working capital purposes.

• Follows Substantial Net Loss

  This capital raise comes after the company reported a substantial net loss of $61.7 million for 2025, highlighting a critical need for funding to support ongoing operations.

auto_awesomeAnalysis

This 424B5 prospectus supplement finalizes the terms for DarioHealth's At-The-Market (ATM) equity offering, enabling the company to sell up to $20 million in common stock. This follows the 8-K filing earlier today which announced the establishment of the program and the S-3 shelf registration from March 19, 2026. Given the company's reported substantial net loss of $61.7 million for 2025, this capital raise is critical for extending its operational runway and addressing outstanding debt. However, the offering represents a potential dilution of approximately 33.78% of current outstanding shares, which is a significant impact for existing shareholders. The proceeds will be used for general working capital, sales and marketing, R&D, M&A, and debt repayment, indicating a broad need for capital.